MM is one of the few visionaries in the biz. At Novartis and Pfizer his R&D record was great and as head of Strategic Alliances in the latter he was also a real performer with a great team too. The issue at AZ was one where he was presiding over R&D and had a dysfunctional BD+L group. They are bottom of the league and despite self congrats on a mkt survey the reality was dropped balls and no engagement with potential portfolio saving partners and M&A targets. It is tough to have a goal for deals and to have no troops able to act. Just look at the batting averages. He will recover.
That is a durn good question. Google Scholar shows ~10-20 scholarly contributions to the literature; I suspect that he did great things at Sandwich? (shrug.)
I think it is worth considering whether or not a single manager can have some sort of impact on a research organization, and I was willing to use MM as a measuring stick. Not anymore, I guess.
Well, AZN did have a market cap of 68 billion when Mackay was hired in May 2010, which has shrunk to 61 billion today.....I'm sure he got an OK severance package.
That said, I don't think a single manager at a big pharma can have the same impact as a QB in football.
Even a broken clock is right twice a day. This is one rare occasions where AZ does something correct. MM was a douche and everybody in the industry, scientist or not, knows it. His track record consists mainly of getting places shut down. He finally got to taste of his of medicine.
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20
Obviously his impact was so great they tossed him out. Which is not surprising.
ReplyDeleteMM is one of the few visionaries in the biz. At Novartis and Pfizer his R&D record was great and as head of Strategic Alliances in the latter he was also a real performer with a great team too. The issue at AZ was one where he was presiding over R&D and had a dysfunctional BD+L group. They are bottom of the league and despite self congrats on a mkt survey the reality was dropped balls and no engagement with potential portfolio saving partners and M&A targets. It is tough to have a goal for deals and to have no troops able to act. Just look at the batting averages. He will recover.
DeleteDear Anonymous,
DeleteMM a visionary? Best laugh I've had all year, I think he is blind.
At Novartis he was crap.
CJ: What is his claim to fame in science, besides being a manager at 5zer?
ReplyDeleteThat is a durn good question. Google Scholar shows ~10-20 scholarly contributions to the literature; I suspect that he did great things at Sandwich? (shrug.)
DeleteI think it is worth considering whether or not a single manager can have some sort of impact on a research organization, and I was willing to use MM as a measuring stick. Not anymore, I guess.
DeleteWell, AZN did have a market cap of 68 billion when Mackay was hired in May 2010, which has shrunk to 61 billion today.....I'm sure he got an OK severance package.
ReplyDeleteThat said, I don't think a single manager at a big pharma can have the same impact as a QB in football.
What? AZ execs didn't possess patience on the proper timescale to see if any of their decisions were right or not? How out of character.
ReplyDeleteEven a broken clock is right twice a day. This is one rare occasions where AZ does something correct. MM was a douche and everybody in the industry, scientist or not, knows it. His track record consists mainly of getting places shut down. He finally got to taste of his of medicine.
ReplyDeleteApplause.